Singapore markets open in 2 hours 51 minutes
  • Straits Times Index

    3,130.24
    +15.16 (+0.49%)
     
  • S&P 500

    3,585.62
    -54.85 (-1.51%)
     
  • Dow

    28,725.51
    -500.09 (-1.71%)
     
  • Nasdaq

    10,575.62
    -161.88 (-1.51%)
     
  • BTC-USD

    19,177.86
    -112.16 (-0.58%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Gold

    1,668.30
    -3.70 (-0.22%)
     
  • Crude Oil

    79.74
    +0.25 (+0.31%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • Nikkei

    25,937.21
    -484.89 (-1.84%)
     
  • Hang Seng

    17,222.83
    +56.93 (+0.33%)
     
  • FTSE Bursa Malaysia

    1,394.63
    -2.87 (-0.21%)
     
  • Jakarta Composite Index

    7,040.80
    +4.60 (+0.07%)
     
  • PSE Index

    5,741.07
    -193.18 (-3.26%)
     

Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today

·2-min read

Shares of the rare disease specialist BioCryst Pharmaceuticals (NASDAQ: BCRX) were up by a noteworthy 20% on heavy volume at 9:38 a.m. ET Thursday morning. Although the biotech reported encouraging 2022 second-quarter results prior to today's opening bell, the real needle mover here appears to be the news that the Food and Drug Administration (FDA) has lifted the partial clinical hold on BCX9930. BCX9930 is an oral Factor D inhibitor indicated for a rare blood disease known as paroxysmal nocturnal hemoglobinuria (PNH).